Since LKB1 loss in lung cancer are associated with immunosuppressive tumor microenvironment and the resistance to immune checkpoint blockade in preclinical models and clinical trials (Skoulidis et al., 2018; Koyama et al., 2016; Kitajima et al., 2019), future research examining the effect of CRTC inhibition in lung cancer genetic mouse models is needed to elucidate the role of CRTC co-activators in lung cancer progression, tumor microenvironment, and therapeutic responses. This evidence concerns the gene CALR and neoplasm.